Pfizer Chief Strategy and Innovation Officer Andrew Baum is stepping down from his executive position to serve as a senior strategic advisor to CEO Albert Bourla. Baum, a former top-tier equity research analyst, joined the pharmaceutical giant in 2024 to provide an outside-in perspective on the company’s portfolio. He will support the executive team through the end of the year before departing the company entirely. Analysts view the move as part of a broader "operational simplification" as the New York-based drugmaker streamlines its leadership structure following a period of massive post-pandemic realignment.
Before jumping to the corporate side, Baum spent decades as a prominent voice in biopharma finance, most notably as the head of global healthcare and managing director for equity research at Citi. His transition to Pfizer was part of a larger trend of Big Pharma firms tapping elite market researchers to lead internal growth strategies. At Pfizer, Baum was tasked with bridging the gap between clinical science and financial performance, a mandate that required navigating the company through a $4 billion cost-realigning initiative and a fluctuating vaccine market.
Despite his short tenure, Baum leaves a significant mark on Pfizer’s long-term pipeline. He was a key architect in the high-stakes $10 billion acquisition of Metsera, a deal that saw Pfizer beat out rivals to secure a foothold in the competitive obesity and metabolic drug market. This acquisition served as a critical pivot after the company’s internal weight-loss candidates stalled. As Baum transitions to his advisory role, his focus shifts to ensuring these major capital allocations and external partnerships are integrated into the company's leaner operating model.